Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2015-01-26 Capital/Financing Update
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that CARMAT is subscribing to a new contingent equity line with Kepler Cheuvreux for up to €50 million. This action involves the potential issuance of new shares and directly relates to the company's fundraising and capital structure management. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a formal annual report (10-K). Since it is a specific announcement about financing, CAP is the most precise classification over the general 'RNS'. The document length is substantial (7769 chars), indicating it is the primary content, not just a brief announcement of a report (RPA).
2015-01-26 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces the establishment of a new flexible equity financing arrangement ('nouveau financement flexible en fonds propres') with Kepler Cheuvreux for a specific amount (€20 M tranche). This type of announcement, detailing fundraising, capital structure changes, or financing agreements, directly corresponds to the definition of 'Capital/Financing Update'. The document is not a full annual report (10-K), an earnings release (ER), or a report publication announcement (RPA) as it contains the substance of the financing deal itself, not just a notice that a report is available. Therefore, the appropriate code is CAP.
2015-01-26 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that CARMAT has been selected for the European SEED1 program to support innovative therapy developers seeking reimbursement. It details the nature of the SEED project (Health Technology Assessment early dialogues) and includes commentary from the CEO. This type of announcement, focusing on a specific business development, regulatory/reimbursement progress, or partnership, is characteristic of an Earnings Release (ER) if it were summarizing financial results, but since it is a specific, non-financial operational/regulatory milestone announcement, it fits best under the general category for significant corporate news that isn't a formal financial report or a standard regulatory filing like a 10-K or IR. Given the options, it is a significant corporate update. While it discusses future reimbursement filings, the core content is the selection announcement. It is not a full financial report (10-K, IR), a transcript (CT), or a management discussion (MDA). It is a press release announcing a specific corporate event/milestone. In many classification schemes, such announcements fall under Earnings Release (ER) if they are periodic, or Regulatory Filings (RNS) if they are mandatory disclosures. Since this is a positive, proactive announcement about regulatory progress, and it is structured as a standard press release, ER is often used for major non-financial news releases, but RNS is the designated fallback for general regulatory announcements. Given the context of HTA/reimbursement progress, it is a significant corporate event announcement. Since it is not a formal financial report, and it is a specific announcement, I will classify it as an Earnings Release (ER) as it functions as a major corporate update, or RNS as a general regulatory announcement. Given the focus on HTA/reimbursement progress, which is regulatory in nature, RNS is a safer fallback, but ER often captures major non-financial press releases. I will lean towards ER as it is a proactive announcement of a significant business development, similar to how preliminary earnings news is often released before the full report. Q2 2015
2015-01-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and announces that CARMAT will benefit from the European SEED program to support innovative therapy designers in the reimbursement process. It details a specific event (dialogue with the HAS scheduled for Q2 2015) and includes standard boilerplate sections like 'A propos de CARMAT' and 'Note de mise en garde'. This format is characteristic of an initial announcement of significant, non-periodic corporate news, rather than a formal regulatory filing like a 10-K, IR, or a specific financial report (ER, MRQ). Since it is a press release announcing a business development/partnership/program inclusion, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement, or potentially an 'Earnings Release' (ER) if it were tied to financial results, but here it is purely operational/strategic news. Given the options, RNS is the most appropriate fallback for a general press release announcing a strategic development that isn't explicitly covered by other codes like DIV, CAP, or MANG.
2015-01-22 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that CARMAT is eligible for the PEA-PME investment scheme, citing specific French regulatory decrees (Décret n° 2014-283). This is a general corporate announcement regarding a regulatory/financial status update that does not fit the specific definitions for Earnings Release (ER), Capital Update (CAP), or a formal regulatory filing like 10-K or IR. Since it is a general, non-periodic corporate announcement concerning eligibility for a specific investment vehicle, it best fits the general 'Regulatory Filings' fallback category (RNS) or potentially a general announcement category. Given the options, RNS (Regulatory Filings) is the most appropriate catch-all for non-standard, official corporate news releases that aren't explicitly defined elsewhere. It is not a report itself, nor a management change, nor a dividend notice.
2015-01-20 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and dated January 19, 2015. It announces a specific operational milestone: a patient implanted with the CARMAT artificial heart has been discharged from the hospital. This type of announcement, focusing on a key operational/clinical event rather than comprehensive financial results (like a 10-K or IR) or a formal shareholder vote, is characteristic of an Earnings Release (ER) or a general operational update. Since it is a press release announcing a significant, positive development (patient discharge and system approval), it fits best under the Earnings Release (ER) category, which often includes operational highlights accompanying financial periods, or potentially Regulatory Filings (RNS) if it were less specific. Given the nature of the announcement (a major clinical milestone update), ER is the most appropriate fit among the provided options, as these releases often contain more than just financial figures. It is not a transcript (CT), a formal report (10-K, IR), or a management discussion (MDA).
2015-01-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.